Detalhe da pesquisa
1.
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML.
Blood
; 141(3): 295-308, 2023 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36260765
2.
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.
Blood
; 138(5): 387-400, 2021 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34351368
3.
CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial.
Cancers (Basel)
; 16(5)2024 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38473278
4.
Injection Site Reactions with Long-Term Pegcetacoplan Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Brief Report.
Adv Ther
; 40(11): 5115-5129, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37707673
5.
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
Blood Adv
; 7(24): 7494-7500, 2023 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37903324
6.
Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.
Future Oncol
; 8(4): 359-71, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22515439
7.
Reliability of Cell-Free DNA and Targeted NGS in Predicting Chromosomal Abnormalities of Patients With Myeloid Neoplasms.
Front Oncol
; 12: 923809, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35774119
8.
Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.
Onco Targets Ther
; 10: 1413-1422, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28331334
9.
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure.
Blood Adv
; 4(13): 2866-2870, 2020 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32589727